Chris Kourtis of Ellerston Capital has a new additions in his fund, ResMed RMD. ResMed, which like CSL, sank further last month after the rise of weight-loss drugs like Ozempic sparked concerns over the companies’ key revenue markets.
“[ResMed] is in the CSL camp. It’s no longer an expensive defensive. It’s now become an oversold, cheap defensive. The market has got it wrong.”
Unperturbed by the Ozempic acolytes, Kourtis likens the Ozempic panic hitting healthcare companies such as CSL and ResMed to the sell-off that hurt Harvey Norman shares in the lead up to Amazon’s launch in Australia back in 2017.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$38.52 |
Change
-0.330(0.85%) |
Mkt cap ! $22.41B | |||
| Open | High | Low | Value | Volume |
| $38.67 | $38.67 | $38.15 | $26.37M | 686.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 361 | $38.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $38.55 | 5000 | 1 |
View Market Depth
| Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
| RMD (ASX) Chart |